CRISPR/Cas9‐mediated targeted editing of AMPK subunits has elucidated its pivotal role in regulating metabolic disorders, while demonstrating that intact AMPK functionality is essential for the antitumor effects of pharmacological activators. The gene discussed is PRKAA2; the disease is metabolic disease.